Impact Factor
4.55
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
11.70
3,372 total citations
h5-index
65
h5 depth signal
Cited share
71.3%
216 of 303
Total citations
3,372
Citation footprint
Metric signal
10.19
External metric anchor
Self-citation
5.8%
197 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
South Korea
512
China
353
United States
194
Japan
103
Singapore
42
Citing Fields of Research
Hepatitis
750
Liver Diseases
597
Liver & Colon Cancer
293
Immunology
45
Substance Abuse
44
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,462
Articles tracked across the journal lifetime
Indexed publication set
303
216 cited publications
Last 12 months
309
38.6 publications/month
Open access share
95.5%
295 OA publications in the last year
Leading citing country
South Korea
512 citing publications
Leading citing field
Hepatitis
750 citing publications
Latest tracked publication
7 October 2026
10 recent records available
Coverage & Indexing History
v18n2, June 2012-
v18n2, June 2012-
Active Coverage
Research Focus & Classification
Indexed Subjects
Hepatitis
Liver Diseases
Liver & Colon Cancer
Issuing & Sponsoring Bodies
Contributor
Taehan Kan Hakhoe
Broad Categories
Gastroenterology
Hepatitis
Liver & Colon Cancer
Liver Diseases
MeSH Descriptors
Biliary Tract Diseases
Liver Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.3350/cmh.2026.0745
Open DOI
Epigenetic and Epitranscriptomic Regulation of Immune Checkpoint Response in Hepatocellular Carcinoma: Mechanisms, Therapeutic Targeting, and Translational Challenges
Clinical and Molecular Hepatology
02
DOI 10.3350/cmh.2026.0693
Open DOI
Immunotherapy and targeted therapy plus hepatic arterial infusion chemotherapy for HCC with portal vein tumor thrombosis (CHANCE2504): a nationwide target trial emulation study
Clinical and Molecular Hepatology
03
DOI 10.3350/cmh.2026.1072
Open DOI
Steatotic liver disease spectrum: From MASLD to MetALD and beyond - Clinical outcomes and precision medicine frontiers
Clinical and Molecular Hepatology
04
DOI 10.3350/cmh.2026.0398
Open DOI
Risk assessment in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-related liver disease: current approaches and future directions
Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction and alcohol-related liver disease (MetALD) exist on a continuous spectrum in which fibrosis stage remains the dominant predictor of liver‑related ...
05
DOI 10.3350/cmh.2026.0659
Open DOI
Alcohol-aware risk stratification and subtype-specific care pathways across metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease
Accurate classification and risk stratification across metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD) depe...
06
DOI 10.3350/cmh.2026.0444
Open DOI
Global epidemiological patterns and disease burden of metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease
The 2023 multisociety Delphi consensus redefined the nomenclature for steatotic liver disease (SLD) by replacing nonalcoholic fatty liver disease with metabolic dysfunction-associated steatotic liver disease (MASLD) and introducing metab...
07
Steatotic liver disease (SLD) is a leading cause of chronic liver disease worldwide impacting more than 30% of the adult population. With the rise of obesity, metabolic syndrome and alcohol use disorder, the prevalence of the two main su...
08
DOI 10.3350/cmh.2026.0954
Open DOI
Prevalence of Steatotic Liver Disease Subtypes based on the MetALD-ALD Prediction Index in the United States
Clinical and Molecular Hepatology
09
DOI 10.3350/cmh.2026.0476
Open DOI
TLR7 agonist plus anti-PD-L1 enhances HBsAg decline and reinvigorates HBV-specific CD8+ T cells: OCEANcure05 RCT study
Clinical and Molecular Hepatology
10
DOI 10.3350/cmh.2026.0820
Open DOI
Toward AI Virtual Cells for Hepatology: Representation, Generation, Dynamics, and Intervention in Single-Cell Models
Clinical and Molecular Hepatology
Bibliographical & Catalog Notes
Also issued online.
Printed on acid-free paper that meets the full ANSI standard for Permanent Paper